

SUPPLEMENTAL AMENDMENT

Please amend the above referenced application as follows:

**In the Specification**

On page 12, line 20, please insert now US patent No. 5,853,722, after "Serial No. 08/217,391."

On page 60, line 34, please insert now US patent No. 5,853,722 after "March 23, 1994."

**In the Claims**

Please add new dependent claims 18-25 as set forth below:

**NEW CLAIM 18**

*q*--18. The antibody of Claim 1, wherein, when administered to a human patient via intravenous infusion, the antibody provides complete complement inhibition at dosages below 0.005g/kg.--

**NEW CLAIM 19**

*o*--19. The antibody of Claim 1, wherein, when administered to a human patient via intravenous infusion, the antibody provides therapeutic benefits at dosages below 0.0022g/kg.--

**NEW CLAIM 20**

*F*  
*sub G*  
--20. The antibody of Claim 19, wherein the antibody is being administered in association with an extracorporeal circulation procedure.--

**NEW CLAIM 21**

--21. A therapeutic agent for use in association with extracorporeal circulation procedures, wherein the therapeutic agent is sterile and non-pyrogenic and comprises the antibody of Claim 1 and a pharmaceutically effective carrier.--

**NEW CLAIM 22**

*15* 14  
--22. The therapeutic agent of Claim 21 wherein the antibody is a humanized immunoglobulin.--

*196*